Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2021 07:00 ET | Source: Silence Therapeutics plc

Silence Therapeutics Welcomes Deep Track Capital as New Shareholder

1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
October 21, 2021 08:30 ET | Source: Silence Therapeutics plc

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
August 12, 2021 07:00 ET | Source: Silence Therapeutics plc

Silence Therapeutics Reports Half-Year 2021 Results

Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to...
October 01, 2020 07:00 ET | Source: Silence Therapeutics plc

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference 1 October 2020 LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) (“Silence” or “the...